Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS

Oramed Pharmaceuticals reported $2.0 million of revenue in 2025 related to the HTIT license settlement and delivered diluted earnings per share of $1.50, results driven by a significant non-operating revaluation gain that produced a $64.016 million net income. Operating performance remained negative, with an operating loss of $15.088 million and minimal gross profit reported. The company continues to reposition its R&D and operational activities through strategic transactions and collaborations. Financial Highlights Revenues: $2.0 million, recognized in 2025 related to the HTIT License Agreement.Gross Profit: $0.013 million, driven by $1.987 million cost of revenue (IIA payment) in 2025.Operating Loss: $(15.088) million, reported as Operating Loss.Net Income: $64.016 million, reflecting large financial income (revaluation gains) net of tax.Diluted income (loss) per share of common stock: $1.50 for the year ended December 31, 2025. Business Highlights Revenue Recognition Shift: Recognized $2.0 million in 2025 from settlement of the HTIT license, representing the first material revenue after prior years of minimal sales.R&D Focus and Asset Transfers: Transferred POD technology and future R&D responsibilities to OraTech/Lifeward; OraTech will bear future oral insulin trial costs.Strategic Investments and Joint Activity: Entered into Lifeward share purchase and notes transactions, acquiring equity, warrants and revenue-sharing rights as part of broader strategic positioning.Clinical Operations Arrangement: Agreed to manage an OraTech clinical trial under a Clinical Trial Management Agreement with reimbursement for services provided.Operational Liquidity and Corporate Strategy: Continued share repurchase activity and redirected operational focus toward strategic reviews, potential pipeline moves, and partnerships.Original SEC Filing: ORAMED PHARMACEUTICALS INC. [ ORMP ] - 10-K - Mar. 26, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.